Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2017-12-19 16:06:402017-12-21 13:44:21Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy